Pharmacologic treatment of psoriatic arthritis and axial spondyloarthritis with traditional biologic and non-biologic DMARDs

Publication date: Available online 22 November 2014 Source:Best Practice & Research Clinical Rheumatology Author(s): Enrique Roberto Soriano , Maria Laura Acosta-Felquer , Phat Luong , Liron Caplan This manuscript focuses on the pharmacologic treatment of psoriatic arthritis and axial spondyloarthritis – including ankylosing spondylitis – using traditional biologic and non-biologic disease-modifying antirheumatic drugs. Early treatment of psoriatic arthritis and axial spondyloarthritis/ankylosing spondylitis as well as the treat-to-target concept receive particular attention. This review also surveys recent national and international guidelines for the treatment of both psoriatic arthritis and couches practice recommendations for axial spondyloarthritis/ankylosing spondylitis within the context of various international guidelines.
Source: Best Practice and Research Clinical Rheumatology - Category: Rheumatology Source Type: research